Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
EDSA

EDSA - Edesa Biotech Inc Stock Price, Fair Value and News

$5.46-1.63 (-22.99%)
Market Closed

15/100

EDSA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

EDSA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EDSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EDSA Price Action

Last 7 days

-24.4%

Last 30 days

-63.6%

Last 90 days

-16.3%

Trailing 12 Months

178.6%

EDSA RSI Chart

EDSA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EDSA Valuation

Market Cap

48.5M

Price/Earnings (Trailing)

-4.65

Price/Sales (Trailing)

19.0K

EV/EBITDA

-3.98

Price/Free Cashflow

-6.45

EDSA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EDSA Fundamentals

EDSA Revenue

Rev. Growth (Yr)

26.71%

Rev. Growth (Qtr)

-35.34%

EDSA Earnings

Earnings (TTM)

-10.4M

Earnings Growth (Yr)

-165.23%

Earnings Growth (Qtr)

-87.68%

EDSA Profitability

Operating Margin

100.00%

EBT Margin

-382525.49%

Return on Equity

-102.42%

Return on Assets

-84.33%

Free Cashflow Yield

-15.5%

EDSA Investor Care

Shares Dilution (1Y)

26.53%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20260000
202578.0K40.3K2.6K0
2024258.9K209.0K153.5K115.8K
2023082.8K154.7K215.7K
20224.0M2.6M780.3K0
20217.4M8.6M10.3M11.1M
2020576.2K568.4K328.8K0
2019298.1K0465.1K518.7K
2018108.0K160.5K211.8K244.4K
2017662.1K501.5K228.3K106.9K
20161.2M1.2M1.3M925.4K
2015604.1K681.4K758.7K1.0M
2014441.5K406.8K372.1K526.8K
201300545.5K476.1K
201200286.1K0
Get all data in R, Python etc through our Historical Stock Data APIs

About Edesa Biotech Inc

EDSA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
 CEO
 WEBSITEedesabiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

Edesa Biotech Inc Frequently Asked Questions

EDSA is the stock ticker symbol of Edesa Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 05 2026, market cap of Edesa Biotech Inc is 48.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 05 2026, EDSA's PE ratio (Price to Earnings) is -4.65 and Price to Sales (PS) ratio is 18.97 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDSA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Edesa Biotech Inc has provided -0.401 (multiply by 100 for percentage) rate of return.